A5056721291- Cardiac Valve Diseases and Treatments
- Cardiac Structural Anomalies and Repair
- Infective Endocarditis Diagnosis and Management
- Mechanical Circulatory Support Devices
- Orthopaedic implants and arthroplasty
- Coronary Interventions and Diagnostics
- Block Copolymer Self-Assembly
- Cardiovascular Disease and Adiposity
- Elasticity and Material Modeling
- Aortic Disease and Treatment Approaches
- Atrial Fibrillation Management and Outcomes
- Dental materials and restorations
- Cardiovascular Function and Risk Factors
- Hydraulic and Pneumatic Systems
- Material Selection and Properties
- Rheology and Fluid Dynamics Studies
- Pulmonary Hypertension Research and Treatments
- Nanofabrication and Lithography Techniques
- Atherosclerosis and Cardiovascular Diseases
- Vibration and Dynamic Analysis
- Injection Molding Process and Properties
- Cardiovascular Health and Disease Prevention
University of Cambridge
2014-2024
Oxford University Hospitals NHS Trust
2021
Royal Adelaide Hospital
2017
The study aims were (1) to identify the community prevalence of moderate or greater mitral tricuspid regurgitation (MR/TR), (2) compare subjects identified by population screening with those known valvular heart disease (VHD), (3) understand mechanisms MR/TR and (4) assess rate valve intervention long-term outcome.Adults aged ≥65 years registered at seven family medicine practices in Oxfordshire, UK screened for inclusion (n=9504). Subjects VHD from hospital records without invited undergo...
Certain styrenic thermoplastic block copolymer elastomers can be processed to exhibit anisotropic mechanical properties which may desirable for imitating biological tissues. The ex-vivo hemocompatibility of four triblock (hard–soft–hard) copolymers with polystyrene hard blocks and polyethylene, polypropylene, polyisoprene, polybutadiene or polyisobutylene soft are tested using the modified Chandler loop method fresh human blood direct contact cell proliferation fibroblasts upon materials....
The potential of polymeric heart valves (PHV) prostheses is to combine the hemodynamic performances biological with durability mechanical valves. aim this work design and develop a new tri-leaflet prosthetic valve (HV) made from styrenic block copolymers. A computational finite element model was implemented optimize thickness leaflets, improve PHV hydrodynamic performances. Based on outcomes, 8 prototypes designed were produced tested in vitro under continuous pulsatile flow conditions, as...
Only mechanical and biological heart valve prostheses are currently commercially available. The former show longer durability but require anticoagulant therapy; the latter display better fluid dynamic behavior do not have adequate durability. New Polymeric Heart Valves (PHVs) could potentially combine hemodynamic properties of valves with valves. This work presents a hydrodynamic evaluation 2 groups newly developed supra-annular, trileaflet prosthetic made from styrenic block copolymers...
Styrene-based block copolymers are promising materials for the development of a polymeric heart valve prosthesis (PHV), and mechanical properties these polymers can be tuned via manufacturing process, orienting cylindrical domains to achieve material anisotropy. The aim this work is computational tool optimization microstructure in new PHV intended aortic replacement enhance performance device. An iterative procedure was implemented orient cylinders along maximum principal stress direction...
A bi-directional, layered microstructure in cylinder forming block copolymers results from the local balance of shear and extensional flow during slow injection moulding.
Here we examine a block copolymer with cylindrical morphology having bio-inspired microstructure of anisotropic orthogonally oriented layers and report changes the under uniaxial strain.
The number of patients requiring replacement heart valves due to valvular disease is forecast rise from 290,000 in 2003 850,000 2050. Currently, treatment these dominated by either surgically implanted mechanical or bioprosthetic valves. Unfortunately, none solutions are optimal, they simply replace native with “prosthetic disease”—mechanical require lifelong anticoagulation, and bioprostheses have a limited durability approximately 15 yr. As such, since the 1950s, researchers sought which...
Major adverse cardiovascular (CV) events (MACE) occur in a substantioal percentage of individuals following acute coronary syndromes (ACS), primarily driven by residual vascular inflammation. Anti-inflammatory drugs have improved CV outcomes but their use is limited significant side-effects. Low-dose interleukin 2 (IL2) increases regulatory T (Treg) cells, which are powerful endogenous regulators the immune response, and could provide new, targeted anti-inflammatory strategy high-risk ACS...
Background/IntroductionAortic Stenosis (AS) is the most frequent valvular pathology in developed world.Whilst much known about its pathogenesis and treatment, a paucity of data exists on prevalence number patients eligible for valve replacement. Aims/ObjectivesTo quantify prevalence, treatment eligibility postoperative survival with AS.
Abstract Surgical repair with implantation of a mitral annuloplasty ring is the gold standard treatment for regurgitation. However, outcomes are variable and recurrent regurgitation not uncommon. A REshapeable Mitral Annuloplasty DevIce (REMADI) proposed, which consists fully encapsulated low melting temperature alloy. The alloy solid rigid at body provides traction force to shape annulus. When heated using noncontact method, melts REMADI becomes malleable. engaged valve annulus anchors...